These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9399612)

  • 1. Cost analysis of the American College of Chest Physicians guidelines for deep vein thrombosis prophylaxis in patients undergoing orthopedic arthroplastic surgery.
    Wade WE; Spruill WJ
    Pharmacotherapy; 1997; 17(6):1286-91. PubMed ID: 9399612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery.
    Hauch O; Khattar SC; Jørgensen LN
    Semin Thromb Hemost; 1991; 17 Suppl 3():280-3. PubMed ID: 1661436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
    Wade WE; Chisholm MA
    Am J Orthop (Belle Mead NJ); 2000 May; 29(5):397-9. PubMed ID: 10868442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty.
    Sculco TP
    Orthopedics; 1996 Aug; 19 Suppl():6-8. PubMed ID: 8856784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
    Olsen J; Gundgaard J; Borris LC
    Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
    [No Abstract]   [Full Text] [Related]  

  • 10. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery.
    Oster G; Tuden RL; Colditz GA
    JAMA; 1987 Jan; 257(2):203-8. PubMed ID: 3098991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost and benefit of prophylaxis against deep vein thrombosis in elective hip replacement. DVT/PE Prophylaxis Consensus Forum.
    Abdool-Carrim T; Adler H; Becker P; Carides M; Ginsberg J; Golele R; Grobler G; Immelman E; Louwrens H; Lukhele M; Veller M; Watt K; Weber F; Williams E
    S Afr Med J; 1997 May; 87(5):594-600. PubMed ID: 9254816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
    Marchetti M; Liberato NL; Ruperto N; Barosi G
    Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
    Krummenauer F; Günther KP; Witzlebf WC
    Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep venous thrombosis prophylaxis in trauma: cost analysis.
    Wade WE; Chisholm MA
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):101-6. PubMed ID: 10691104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery.
    Dainty L; Maxwell GL; Clarke-Pearson DL; Myers ER
    Gynecol Oncol; 2004 May; 93(2):366-73. PubMed ID: 15099947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for long-term prophylaxis of venous thromboembolism.
    Agnelli G; Mancini GB; Biagini D
    Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
    Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.